@article{3104957,
    title = "Consensus statement on the management of waldenström macroglobulinemia patients during the COVID-19 pandemic",
    author = "Talaulikar, D. and Advani, R.H. and Branagan, A.R. and Buske, C. and Dimopoulos, M.A. and D'Sa, S. and Kersten, M.J. and Leblond, V. and Minnema, M.C. and Owen, R.G. and Palomba, M.L. and Tedeschi, A. and Trotman, J. and Varettoni, M. and Vos, J.M. and Treon, S.P. and Kastritis, E. and Castillo, J.J.",
    journal = "Hemasphere",
    year = "2020",
    volume = "4",
    number = "4",
    publisher = "Ovid Technologies (Wolters Kluwer Health)",
    doi = "10.1097/HS9.0000000000000433",
    keywords = "immunoglobulin M, Article;  clinical trial (topic);  consensus;  consultation;  coronavirus disease 2019;  human;  pandemic;  patient care;  patient participation;  priority journal;  serology;  treatment indication;  Waldenstroem macroglobulinemia",
    abstract = "In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others. Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited."
}